Introduction: Giant cell tumour of bone (GCTB) is a locally aggressive and osteolytic tumour. The peak incidence is during the third and fourth decades of life. The majority of tumours occur in the meta-epiphyseal (end) region of the long bones. Surgical resection is the preferred treatment option, if possible but it is a tumor which always poses progressive problems. Denosumab is indicated in recurrent or unresectable GCTB. Materials & Methods: We report a series of 70 patients treated for GCT at the medical oncology department of the CPMC of Algiers in collaboration with the orthopedics department of Mustapha University Hospital between between December 2018 to December 2023. Results: 70 patients (50 women and 20 men). The sex ratio is 0.54. The average age is 22 years (11-54 years). Reason for Consultation:  Pathological fracture: n=10 -Pain: n=30 - Functional impotence: n=20 - Tumor mass: n=5 - Concept of trauma: n=5 • Stage of the disease: -Localized: n=29 -Recurrence: n=30, -Recurrence + pulmonary metastases: n=10,  Sarcomatous transformation: n=1 • Type of treatment: -Radiotherapy, n=1 -Exercised biopsy: n=10, -Curettage + cementoplasty: n=50  Exeresis with osteosynthesis material: n=8, -Amputation: n=1 • Medical treatment: Denosumab: n=45 • The number of courses with denosumab was between 6 and 55 cycles . Denosumab was administered neoadjuvantly in 10 patients, in 20 patients with reccurence disease, 15 patients in the metastatic phase  In terms of toxicity we noted hypocalcemia moderate in 3 patients. Objective Responses: 95% clinical response, 5 complete radiological responses and 10 partial responses, 20 stable patients and 9 out of 10 patients who received neoadjuvant denosumab were able to operate. Progression Free Survival is 28 months. Conclusion: GCTs are aggressive tumors with intermediate malignancy that should not be underestimated. The treatment is essentially surgical. Denosumab is indicated for both neoadjuvant and adjuvant use, it allows obtaining a clear clinical and radiological improvement.

Radiotherapy is a cornerstone in the treatment of Hodgkin's disease but can have long-term consequences, notably the development of secondary malignant tumors. This case study and literature review highlight the imaging characteristics, diagnostic challenges, and clinical outcomes of this late complication. The aim of this article is to underscore the role of imaging modalities in the diagnosis, characterization, and management of this rare and complex condition. We discuss the radiological findings, clinical diagnosis, and therapeutic considerations, thereby providing valuable insights into radio-induced breast cancer in Hodgkin's disease and emphasizing the importance of personalized surveillance in these high-risk patients.

: Granulosa tumors are rare ovarian tumors with a better prognosis compared to other ovarian tumors. Their progression is usually slow, and the tumor remains confined to the ovary for a long time. The adult form characterized by microfollicular proliferation, a coffee bean appearance and Call Exner bodies is the most common. The solidocystic appearance of these tumors is generally nonspecific and diagnosis can be difficult preoperatively. However, the hormonal secretion that accompanies it helps guide the diagnosis and guide treatment. Surgery remains the basis of treatment and must be extensive in elderly patients. It carries a risk of recurrence which can occur several years after the excision surgery. We report the observation of a 38-year-old patient with a history of a mother suffering from breast cancer, who presented with a granulosa tumor of the left ovary diagnosed postoperatively. The epidemiological, clinical and therapeutic aspects are discussed.